Healthcare legislation firm Frier Levitt has analyzed FDA enforcement actions towards “investigation only” peptide vendors. Their conclusion: the FDA considers a product’s classification determined by its supposed use, not its disclaimers. When websites consist of dosage guides, reconstitution instr